ato
develop
new
polymeras
chain
reaction
pcr
base
assay
nucleic
acid
detect
infecti
diseasesbdevelop
new
assay
demand
emerg
infecti
diseas
exampl
proper
nucleic
acidbas
test
exist
detect
influenza
viru
lab
parasitolog
research
unit
aim
fill
gap
develop
abil
cextens
technolog
rapid
detect
use
fast
pcr
reaction
test
use
point
care
diagnost
testsreal
time
pcr
test
detect
viru
load
reliabl
pcrbase
diagnost
direct
test
detect
presenc
infecti
microorgan
done
properli
extrem
reliabl
give
consist
reproduc
result
posit
result
singl
band
specif
size
particular
locat
agaros
gel
specif
oligonucleotid
design
well
pcr
reaction
give
singl
band
specif
particular
microorgan
absenc
microorgan
presenc
differ
microorgan
band
seen
sensit
pcr
reaction
amplifi
even
minuscul
amount
genet
materi
time
sensit
elisabas
techniqu
detect
signal
infect
well
establish
furthermor
wane
infect
pcr
signal
drop
immun
signal
remain
give
erron
result
flexibl
multipl
reaction
run
singl
tube
give
result
appear
multipl
marker
band
microorgan
better
cross
check
result
speed
pcr
reaction
rel
quick
perform
mani
sampl
analys
singl
run
whole
plate
run
also
much
cheaper
convent
assay
market
trend
also
indic
current
screen
tool
involv
antibodi
detect
elisa
method
replac
detect
base
molecular
techniqu
pcr
furthermor
current
molecular
diagnost
product
consist
mainli
test
design
around
singl
biomark
associ
diseas
state
next
gener
molecular
diagnost
techniqu
microarray
develop
diagnosi
variou
infecti
diseas
cancer
genet
disord
project
groundwork
tap
opportun
symbiot
relationship
pharmaceut
compani
diagnost
laboratori
assist
drug
discoveri
process
develop
diagnost
test
although
pcrbase
diagnost
servic
avail
eastern
india
well
organ
profession
manag
becom
commerci
viabl
busi
option
pcrbase
diagnost
still
novelti
stage
certain
pcrbase
test
use
support
test
elisabas
kit
reason
follow
lack
unifi
approach
vision
sever
lack
personnel
adequ
techno
commerci
background
make
strateg
plan
test
pursu
design
execut
test
well
busi
acumen
transform
test
highli
special
novelti
item
easytodo
mass
servic
part
everi
clinic
laboratori
hospit
lack
hand
technic
knowledg
among
establish
pathologist
region
partli
due
commerci
consider
partli
due
lack
adequ
molecular
biolog
train
medic
colleg
pathologist
expertis
carri
test
well
interpret
result
result
test
gain
popular
presenc
organ
lobbi
promot
elisabas
test
manufactur
distributor
diagnost
kit
citi
strong
lobbi
oppos
introduct
newer
diagnost
test
replac
exist
test
includ
govern
regulatori
author
approv
test
competit
amongst
patholog
laboratori
cut
competit
amongst
laboratori
test
test
result
send
test
laboratori
outsid
kolkata
simpl
test
simpl
independ
laboratori
tap
busi
potenti
lack
valid
test
suitabl
indian
condit
reagent
import
abroad
valid
studi
carri
see
suitabl
condit
henc
test
often
turn
unreli
result
medic
commun
trust
india
promis
big
market
molecular
diagnost
primarili
due
increas
health
awar
demand
afford
qualiti
healthcar
compound
fact
number
insur
live
increas
recent
medicoleg
implic
necessit
conduct
test
furthermor
decis
doctor
base
lab
report
facil
increasingli
becom
avail
town
rural
area
plan
proceed
follow
line
develop
test
valid
subsequ
licens
commerci
develop
pcrbase
test
valid
lab
technic
abil
develop
pcrbase
test
base
technic
knowhow
avail
scientif
literatur
test
develop
valid
sampl
popul
valid
test
use
clinic
laboratori
commerci
technolog
licens
test
valid
licens
patholog
lab
hospit
commerci
ntroduc
fast
pcrbase
techniqu
rapid
detect
infect
min
detect
test
develop
potenti
revolution
pcr
way
almost
becom
point
care
diagnost
test
introduc
new
test
develop
test
rapidli
emerg
need
lab
introduc
one
new
test
everi
month
particularli
area
test
exist
main
advantag
pcrbase
diagnost
reliabl
accuraci
newer
instrument
develop
test
even
faster
faster
pcr
test
would
mean
test
done
point
care
type
diagnost
doctor
chamber
wherea
tradit
pcr
run
gel
run
take
three
hour
give
result
h
min
pcr
run
anoth
min
gel
run
newer
pcr
system
develop
complet
run
min
result
obtain
within
hour
improv
also
carri
test
result
view
colourimetr
posit
result
indic
appear
singl
colour
tube
abil
lab
technic
abil
singlemind
focu
determin
area
pcrbase
diagnost
transform
test
commerci
viabl
test
compet
test
alreadi
avail
market
lab
hope
get
first
player
advantag
excit
field
area
diagnost
india
studi
preliminari
pcrbase
assay
conduct
india
indian
sampl
like
mycobacteria
hepat
hiv
bacteri
viral
diseas
give
us
lead
design
primer
pcrbase
test
develop
isol
laboratori
work
specif
microorgan
nowher
systemat
studi
multipl
pathogen
carri
detect
dna
rna
furthermor
studi
carri
systemat
multiplex
pcr
intern
studi
simpl
pcrbase
assay
routin
use
lab
abroad
howev
sinc
strain
differ
india
test
need
redesign
indian
condit
exampl
pcrbase
assay
done
bacteri
cultur
tuberculosi
genet
marker
specif
mycobacterium
tuberculosi
well
establish
bioconsort
access
primer
posit
result
look
like
gel
fig
hepat
caus
agent
jaundic
difficult
distinguish
b
c
type
earli
stage
infect
howev
distinguish
pcrbase
techniqueshepat
b
dna
viru
straightforward
test
blood
patient
result
singl
clean
bandhepat
c
caus
agent
jaundic
rna
viru
therefor
revers
transcriptionpcr
need
done
nest
pcr
might
necessari
get
clean
band
pi
design
pcrbase
assay
detect
tuberculosi
phosphat
specif
transport
gene
use
detect
tuberculosi
accur
similar
assay
develop
uniqu
protein
pathogen
pi
also
design
rt
pcr
assay
detect
drug
resist
strain
tuberculosi
result
illustr
fig
research
methodolog
use
follow
design
pcr
primer
identif
infecti
diseas
pathogen
import
step
pcrbase
diagnost
primer
develop
uniqu
sequenc
pathogen
sequenc
part
full
avail
gene
bank
databas
primer
design
multiplex
multipl
primer
need
design
use
singl
reaction
lab
expertis
design
primer
make
sure
selfann
primer
readi
pcr
condit
standard
assay
collect
blood
extract
genet
materi
genet
materi
extract
ml
blood
briefli
spun
pellet
cell
plasma
treat
chemic
lyse
cell
free
genet
materi
pass
qiagen
qiaamp
column
similar
column
procur
indian
manufactur
wash
suppli
buffer
precipit
alcohol
get
dna
pcr
reaction
set
use
dnafor
rna
virus
addit
step
requir
rna
extract
way
dna
revers
transcript
reaction
carri
convert
rna
cdna
pcr
reaction
carri
use
cdna
pcr
reaction
pcr
reaction
carri
either
dna
cdna
assay
condit
standard
follow
condit
anneal
temperatur
rang
use
highest
temperatur
give
singl
band
chosen
multiplex
pcr
condit
standard
howev
assum
sinc
primer
exact
match
dna
sequenc
temperatur
give
optimum
resultsno
cycl
reduc
number
cycl
time
reaction
cycl
cycl
cycl
cycl
reaction
tri
analyz
result
agaros
gel
result
analys
agaros
gel
band
size
compar
posit
control
kept
purpos
blank
lane
neg
control
indic
clean
pcr
reaction
contamin
composit
gel
gel
run
condit
standard
minim
time
cost
reaction
valid
assay
assay
valid
elisabas
test
alreadi
avail
market
sampl
size
use
valid
test
reliabl
assay
assay
valid
knowhow
methodolog
conduct
studi
licensedw
develop
valid
follow
assay
phase
wise
manner
phase
commerci
import
assay
develop
follow
tuberculosi
hepat
bhepat
c
three
first
two
dna
virus
third
one
rna
viru
pcr
revers
transcriptas
assay
develop
urgent
need
assay
first
assay
develop
first
simpl
pcr
assay
develop
follow
multiplex
pcr
nest
pcr
necessarytim
budget
permit
follow
assay
also
attempt
promis
one
taken
forwardhepat
c
viru
rna
hepat
e
viru
rna
plasmodium
falciparum
plasmodium
vivax
salmonella
typhi
vibrio
cholera
phase
soon
first
phase
test
develop
introduc
new
upcom
technolog
rapid
pcr
quick
diagnost
infecti
diseas
pathogen
use
almost
poc
medicin
use
reagent
develop
earlier
assay
slight
modif
phase
second
year
newer
rarer
assay
develop
per
need
industri
consult
physician
lab
develop
assay
detect
follow
infecti
agent
chlamydia
pneumonia
clostridium
botulinum
mycoplasma
pneumonia
neisseria
gonorrhoea
dengu
viru
rna
japanes
enceph
viru
rna
polioviru
rna
mump
viru
rna
rabi
viru
rna
enter
adenoviru
measl
viru
avian
influenza
viru
sar
coronavirusinfluenza
viru
variou
form
rotaviru
rna
exhal
breath
condens
ebc
condens
exhal
breath
collect
use
refriger
devic
variou
volatil
molecul
water
diffus
cell
line
airspac
lung
airway
mouth
analysi
exhal
breath
also
reveal
presenc
nonvolatil
particl
droplet
may
form
due
turbul
airway
chang
surfac
tension
alveoli
airway
airway
line
fluid
alf
collect
gase
exhal
air
form
ebc
ebc
compris
water
vapour
varieti
volatil
nitric
oxid
carbon
monoxid
hydrocarbon
nonvolatil
urea
gsh
leukotrien
prostanoid
cytokin
compon
composit
ebc
complet
understood
exhal
breath
condens
ebc
increasingli
gain
popular
field
lung
diseas
due
noninvas
natur
variou
oxid
stress
marker
inflammatori
mediat
inflammatori
cytokin
reactiv
oxygennitrogen
speci
oxid
glutathion
may
estim
use
ebc
therefor
may
use
detect
discov
novel
marker
differ
lung
diseas
howev
small
amount
ebc
obtain
patient
pose
hurdl
applic
detect
variou
lung
ailment
moreov
abil
replic
alf
still
remain
test
standard
use
ebc
diagnosi
comparison
need
optim
dilut
factor
use
differ
patient
lung
ailment
asthma
chronic
obstruct
pulmonari
diseas
copd
involv
inflamm
airway
lung
inflamm
current
assess
use
invas
techniqu
bronchoscopi
bronchial
biopsi
bronchoalveolar
lavag
bal
fluid
analysi
sputum
induct
serum
urin
biomark
may
reflect
system
inflamm
assess
assist
design
pharmacolog
therapi
patient
manag
diseas
mention
previous
exhal
breath
compris
volatil
eg
nitric
oxid
carbon
monoxid
hydrocarbon
nonvolatil
compon
nitric
oxid
measur
standard
method
assess
airway
inflamm
current
asthma
patient
glucocorticoid
treatment
measur
use
monitor
patient
health
complianc
pharmacotherapi
use
ebc
estim
prove
clinic
util
ebc
collect
perform
use
homemad
commerci
avail
apparatu
apparatu
gener
consist
doubl
wall
glass
contain
cool
insid
use
ice
liquid
nitrogen
jacket
tube
collect
system
consist
tube
connect
glass
contain
one
end
mouth
piec
end
patient
requir
breath
mouth
noseclip
mouth
piec
min
ebc
collect
doubl
wall
glass
contain
outer
contain
depend
respiratori
paramet
condens
surfac
temperatur
turbul
airflow
ml
ebc
may
collect
variou
commerci
avail
ebc
collect
system
avail
one
exampl
jaegertonni
hoechberg
germani
design
equip
similar
homemad
devic
apart
abil
collect
sampl
frozen
state
may
use
collect
volatil
substanc
ebc
howev
temperatur
cool
apparatu
fluctuat
lead
collect
ebc
mix
form
inconsist
ebc
collect
result
differ
concentr
report
differ
studi
analysi
multipl
analyt
collect
vial
need
replac
smaller
vial
scalingup
oper
cost
condens
also
consid
ii
use
assess
respiratori
paramet
collect
may
connect
pneumotachograph
comput
enabl
record
respiratori
paramet
onlin
addit
ecoscreen
ii
capabl
collect
ebc
airway
alveoli
separ
compartmentsbag
enabl
comparison
ebc
two
normal
diseas
state
surfac
collect
system
plastic
vs
teflonco
metal
may
also
appropri
collect
compound
lipid
howev
publish
studi
avail
condens
respiratori
research
inc
charlottesvil
va
anoth
commerci
avail
portabl
condens
compris
dispos
polypropylen
collect
system
aluminium
sleev
around
refriger
temperatur
cool
may
chosen
user
due
portabl
natur
easili
use
longitudin
studi
measur
requir
multipl
time
day
polypropylen
collect
bag
easili
store
refriger
home
howev
temperatur
home
refriger
may
differ
laboratori
freezer
may
result
loss
volatil
compound
design
also
prevent
salivari
contamin
also
use
determin
ph
ebc
use
respiratori
research
inc
charlottesvil
va
ph
measur
suffici
volum
may
collect
minut
collect
ebc
still
need
taken
laboratori
biochem
test
comparison
ebc
collect
rtube
ecoscreen
report
higher
volum
condens
detect
lipid
protein
mediat
ebc
collect
ecoscreen
studi
address
issu
requir
standard
steril
protocol
ebc
equip
necessari
reduc
cross
contamin
current
equip
steril
use
antibacteri
solut
sodium
hypochlorit
h
follow
rins
water
effect
differ
collect
materi
compon
ebc
unknown
ecoscreen
condens
coat
ei
du
pont
de
nemour
compani
inc
washington
de
avoid
loss
molecul
adher
servic
borosil
glass
coat
found
better
silicon
aluminium
polypropylen
teflon
albumin
detect
result
suggest
condens
materi
need
accord
moleculescompound
detect
use
separ
sensor
simultan
collect
differ
compound
hydrogen
peroxid
inflammatori
mediat
may
develop
effect
antisept
solut
use
clean
optim
collect
protocol
enabl
simultan
collect
materi
requir
fig
reactiv
oxygen
speci
ro
reactiv
nitrogen
speci
rn
among
biomark
detect
ebc
use
mani
lung
diseas
studi
format
sever
rn
start
nitric
oxid
volatil
compon
ebc
synthes
nitric
oxid
synthas
no
amino
acid
arginin
respiratori
tract
contain
sever
differ
type
cell
airway
epitheli
cell
alveolar
epitheli
cell
macrophag
eosinophil
neutrophil
smooth
muscl
cell
mast
cell
contain
no
ro
superoxid
anion
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
end
document
react
form
unstabl
highli
reactiv
peroxynitrit
peroxynitrit
anion
aid
nitros
tyrosin
residu
form
measur
hplc
ms
also
react
thiol
like
glutathion
cystein
protein
thiol
residu
form
snitrothiol
rsno
rsno
measur
colourimetr
final
metabol
nitrit
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
end
document
nitrat
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
end
document
patient
asthma
adult
children
found
high
level
nitrit
nitrat
ebc
one
studi
show
asthmat
adult
treat
glucocorticoid
lower
level
nitritenitr
ebc
compar
patient
treat
steroid
nitrit
concentr
ebc
increas
asthma
exacerb
sever
case
nitrit
nitrat
concentr
ebc
measur
assay
colourimetr
chemiluminesc
fluorimetr
chromatographi
ion
ga
liquid
hydrogen
peroxid
anoth
volatil
molecul
ebc
sever
cell
type
produc
superoxid
dismutas
sod
convers
superoxid
anion
releas
inflammatori
structur
cell
includ
neutrophil
eosinophil
macrophag
epitheli
cell
detect
ebc
probabl
unstabl
oxid
stress
marker
like
isoprostan
like
rn
found
increas
peopl
affect
asthma
copd
ard
treatment
montelukast
effect
content
ebc
mildli
asthmat
patient
wherea
treatment
triamcinolon
acetonid
reduc
content
limit
assess
ebc
instabl
mean
sampl
collect
fresh
frozen
later
assay
measur
assay
colourimetr
chemiluminesc
fluorimetr
assay
anoth
biomark
oxid
stress
malondialdehyd
mda
form
degrad
polyunsatur
lipid
ro
mda
present
ebc
measur
rang
nm
hplc
oxid
stress
inflamm
respiratori
tract
lead
increas
ro
rn
use
indic
patient
asthma
copd
cystic
fibrosi
idiopath
pulmonari
fibrosi
ipf
high
level
rsno
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
end
document
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
text
end
document
mda
ebc
apart
airway
line
fluid
alf
also
antioxid
compound
like
cystein
cy
glutathion
gsh
ebc
contain
gsh
magnitud
nm
compar
bronchoalveolar
lavag
fluid
balf
contain
gsh
magnitud
assess
ebc
noninvas
techniqu
use
sampl
lower
airway
collect
ebc
involv
tidal
breath
inhal
exhal
rest
breath
collect
devic
chill
chill
collect
devic
allow
water
vapour
ebc
condens
collect
quantit
differ
mediat
factor
done
collect
condens
mediat
quantifi
origin
epitheli
line
fluid
elf
get
mobil
expir
differ
inflammatori
mediat
simpl
prooxid
molecul
larger
protein
found
ebc
patient
diseas
like
copd
asthma
acut
respiratori
distress
syndrom
ard
despit
promis
noninvas
techniqu
sever
question
rais
regard
methodolog
delay
adopt
clinic
techniqu
standard
method
collect
ebc
differ
investig
use
collect
devic
rang
teflon
tube
convect
cylind
ice
bath
thu
use
ebc
mainstream
standard
method
collect
must
determin
nowaday
ebc
collect
devic
like
rtubetm
respiratori
research
inc
usa
ecoscreen
viasi
commerci
avail
also
problem
dilut
ebc
respiratori
droplet
get
dilut
often
much
fold
collect
watersatur
exhal
breath
pose
problem
mediat
solubl
factor
alreadi
present
low
concentr
detect
verysensit
test
detect
especi
problem
case
protein
may
get
aerosol
dilut
may
differ
among
test
subject
make
difficult
standard
test
american
thorac
societi
well
european
respiratori
societi
issu
guidelin
collect
ebc
attempt
address
abovement
issu
suggest
standard
ebc
mediat
may
done
measur
quantiti
nonvolatil
cation
ebc
consid
give
idea
degre
dilut
cation
level
elf
remain
somewhat
constant
howev
method
work
ebc
lyophil
ammonia
remov
may
lead
chang
level
biomark
regardless
issu
ebc
analysi
potenti
power
techniqu
assess
lung
diseas
seen
sever
studi
ebc
patient
copd
differ
normal
peopl
ebc
profil
chang
treatment
show
assess
ebc
help
diagnosi
treatment
lung
diseas
mediat
present
ebc
copd
patient
includ
hydrogen
peroxid
hydrocarbon
like
isoprostan
cytokin
studi
hydrogen
peroxid
h
deriv
superoxid
radic
produc
neutrophil
airway
marker
oxid
stress
underli
inflamm
airway
ebc
copd
patient
higher
level
compar
healthi
control
level
rise
exacerb
diseas
level
measur
ebc
correl
sever
diseas
measur
ratio
level
ebc
copd
patient
reduc
nacetylcystein
antioxid
studi
need
determin
effect
copd
use
biomark
diagnosi
copd
indic
neutrophil
inflamm
sinc
neutrophil
predomin
airway
copd
also
measur
ebc
done
easili
use
inexpens
chemic
isoprostan
isoprostan
prostaglandinlik
compound
form
free
radicalcatalyz
peroxid
essenti
fatti
acid
like
arachidon
acid
without
action
enzym
cyclooxygenas
cox
chemic
stabl
form
vivo
consid
marker
lipid
peroxid
oxid
stress
human
isoprostan
thoroughli
studi
marker
oxid
stress
human
lung
diseas
may
import
develop
copd
sever
studi
shown
level
higher
ebc
copd
patient
normal
healthi
control
level
found
increas
exacerb
diseas
howev
measur
pulmonari
function
show
correl
pulmonari
function
copd
patient
also
smoker
higher
level
nonsmok
copd
patient
thu
use
marker
underli
inflamm
airway
isoprostan
measur
use
commerci
immunoassay
kit
mediat
marker
oxid
stress
like
aldehyd
found
ebc
instabl
lack
specif
limit
use
clinic
ebc
copd
patient
lower
ph
normal
thu
use
marker
airway
inflamm
cytokin
also
found
ebc
low
level
rang
pgml
level
interleukin
found
higher
copd
patient
rang
marker
found
ebc
copd
patient
show
potenti
ebc
tool
diagnosi
andor
treatment
copd
sever
marker
detect
ebc
asthma
patient
includ
leukotrien
lt
anoth
factor
consid
marker
ph
hydrogen
peroxid
h
ebc
heavi
smoker
patient
sever
asthma
found
high
level
level
ebc
patient
sever
allerg
asthma
show
invers
correl
pulmonari
function
measur
test
antiinflammatori
therapi
asthma
patient
shown
improv
along
declin
level
eicosanoid
eicosanoid
group
compound
includ
prostaglandin
relat
compound
form
arachidon
acid
leukotrien
lt
eicosanoid
measur
ebc
enzym
immunoassay
gcm
ga
chromatographymass
spectrometri
cysteinyl
leukotrien
cyslt
found
ebc
asthmat
patient
level
seem
correl
sever
diseas
found
reduc
antiinflammatori
drug
also
found
ebc
asthmat
patient
correl
diseasesever
howev
level
get
complet
suppress
treatment
corticosteroid
mayb
indic
airway
inflamm
ph
sever
studi
found
ebc
asthmat
patient
ph
lower
normal
ph
exacerb
diseas
lead
decreas
ph
restor
corticosteroid
treatment
advantag
use
ph
marker
ebc
includ
low
cost
collect
good
reproduc
avail
standard
refer
exhal
nitric
oxid
eno
exhal
nitric
oxid
eno
consid
sensit
marker
airway
inflamm
especi
allerg
asthma
higher
level
eno
indic
exacerb
diseas
also
indic
loss
asthma
control
correl
found
level
eno
allergen
challeng
especi
late
asthmat
respons
lar
allerg
rhiniti
hay
fever
inflamm
nose
occur
immun
system
react
allergen
air
ebc
peopl
allerg
rhiniti
also
contain
sever
mediat
use
marker
diseas
like
ebc
asthmat
eno
ebc
peopl
suffer
allerg
rhiniti
contain
nasal
nitric
oxid
nno
standard
techniqu
develop
measur
airway
current
nno
measur
use
portabl
analyz
mino
result
valid
result
standard
chemiluminesc
assay
thu
techniqu
noninvas
easi
quick
use
tool
diagnosi
gener
nno
level
rang
part
per
billion
ppb
paranas
sinus
produc
high
level
nno
ppm
action
induc
nitric
oxid
synthas
ino
epithelium
seen
inhibitor
no
administ
healthi
individu
nno
level
drop
lead
inflamm
sinu
evid
ebc
contain
sever
molecul
may
consid
biomark
markerprofil
ebc
vari
type
diseas
sever
imper
techniqu
collect
ebc
measur
standard
tough
ask
marker
differ
stabil
solubl
volatil
concentr
result
one
techniqu
enough
measur
differ
molecul
present
one
main
limit
ebc
measur
low
concentr
biomark
thu
limit
measur
due
assay
sensit
enough
possibl
potent
antibodi
develop
sensit
assay
also
ensu
easili
detect
real
time
use
electrod
coat
horseradish
peroxidas
similar
enzymebas
assay
may
develop
lipid
mediat
like
molecular
biosensor
may
develop
detect
low
concentr
certain
molecul
dispos
detector
stick
may
also
develop
help
collect
ebc
monitor
profil
clearli
ebc
novel
techniqu
great
potenti
noninvas
diagnosi
treatment
variou
lung
diseas
especi
inflammatori
diseas
like
asthma
copd
rhiniti
